Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06104592 · ClinicalTrials.gov registry record · Phase 2
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
A Phase 2 study of Large B-cell Lymphoma and Relapsed Non-Hodgkin Lymphoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT06104592: Recruiting Phase 2 study of Large B-cell Lymphoma and Relapsed Non-Hodgkin Lymphoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT06104592 is a Phase 2 study of Large B-cell Lymphoma and Relapsed Non-Hodgkin Lymphoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 27 participants, below the 158-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06104592, a Phase 2 study of Large B-cell Lymphoma and Relapsed Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Primary Outcome
PFS will be measured by date of CAR T-cell infusion until first occurrence of in-field, local, or distant progression, or death. If none of these events occur, patients will be censored on date of last contact.
Conditions Studied
Interventions
- BIOLOGICAL Chimeric Antigen Receptor T-Cell Therapy
- RADIATION Comprehensive Ablative Bridging Irradiation (CABI)
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT06104592 shows while recruiting
NCT06104592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 158-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Chimeric Antigen Receptor T-Cell Therapy is the first listed.
NCT06104592 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06104592 about?
NCT06104592 is a clinical study titled "Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL". This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
What is the current status of trial NCT06104592?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2023-11-08. Estimated completion is 2026-12.
What conditions does trial NCT06104592 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06104592?
The interventions under investigation include: Chimeric Antigen Receptor T-Cell Therapy (BIOLOGICAL), Comprehensive Ablative Bridging Irradiation (CABI) (RADIATION).
Who is sponsoring clinical trial NCT06104592?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06104592 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06104592's enrollment target sits among peer trials
27 21st of 28 higher than 8 of 28 other Large B-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Large B-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
CAR-T Followed by Bispecific Antibodies
RECRUITING · Phase 2
-
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RECRUITING · Phase 2
-
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
RECRUITING · Phase 2
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI